Compass Therapeutics (NASDAQ:CMPX) Receives “Buy” Rating from Guggenheim

Guggenheim restated their buy rating on shares of Compass Therapeutics (NASDAQ:CMPX) in a research note published on Wednesday morning,Benzinga reports. The firm currently has a $12.00 target price on the stock.

Several other brokerages have also recently weighed in on CMPX. Piper Sandler began coverage on Compass Therapeutics in a research note on Wednesday, February 19th. They set an “overweight” rating and a $12.00 price objective on the stock. HC Wainwright reissued a “buy” rating and set a $10.00 price target on shares of Compass Therapeutics in a research report on Wednesday, January 8th. Jefferies Financial Group upped their price objective on shares of Compass Therapeutics from $7.00 to $8.00 and gave the stock a “buy” rating in a research report on Monday, February 10th. Wedbush reissued an “outperform” rating and set a $8.00 target price on shares of Compass Therapeutics in a research report on Tuesday. Finally, Leerink Partners raised Compass Therapeutics from a “market perform” rating to an “outperform” rating and upped their target price for the company from $4.00 to $6.00 in a report on Wednesday. One analyst has rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat, Compass Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $11.63.

Compass Therapeutics Price Performance

NASDAQ:CMPX opened at $1.69 on Wednesday. Compass Therapeutics has a one year low of $0.77 and a one year high of $4.08. The company has a market cap of $233.70 million, a PE ratio of -4.57 and a beta of 1.19. The firm has a 50-day moving average of $2.81 and a 200-day moving average of $2.11.

Compass Therapeutics (NASDAQ:CMPX) last issued its quarterly earnings data on Thursday, February 27th. The company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.01). On average, equities research analysts expect that Compass Therapeutics will post -0.36 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in CMPX. Squarepoint Ops LLC purchased a new stake in Compass Therapeutics during the fourth quarter valued at about $35,000. Tang Capital Management LLC lifted its stake in shares of Compass Therapeutics by 225.4% during the 4th quarter. Tang Capital Management LLC now owns 5,900,000 shares of the company’s stock valued at $8,555,000 after buying an additional 4,087,005 shares in the last quarter. ProShare Advisors LLC boosted its holdings in Compass Therapeutics by 49.0% in the 4th quarter. ProShare Advisors LLC now owns 28,722 shares of the company’s stock worth $42,000 after buying an additional 9,451 shares during the period. MPM Bioimpact LLC grew its stake in Compass Therapeutics by 51.9% in the 4th quarter. MPM Bioimpact LLC now owns 8,567,896 shares of the company’s stock valued at $12,423,000 after buying an additional 2,926,002 shares in the last quarter. Finally, Enavate Sciences GP LLC bought a new stake in Compass Therapeutics during the 4th quarter valued at $11,293,000. Hedge funds and other institutional investors own 68.43% of the company’s stock.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.